Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants

• Published in: bioRxiv
• Main Authors: Addetia, Amin, Piccoli, Luca, Case, James Brett, Park, Young-Jun, Beltramello, Martina, Guarino, Barbara, Dang, Ha, Pinto, Dora, Scheaffer, Suzanne, Sprouse, Kaitlin, Bassi, Jessica, Silacci-Fregni, Chiara, Muoio, Francesco, Dini, Marco, Vincenzetti, Lucia, Acosta, Rima, Johnson, Daisy, Subramanian, Sambhavi, Saliba, Christian, Giurdanella, Martina, Lombardo, Gloria, Leoni, Giada, Culap, Katja, McAlister, Carley, Rajesh, Anushka, Dellota, Exequiel, Zhou, Jiayi, Farhat, Nisar, Bohan, Dana, Noack, Julia, Lempp, Florian A, Cameroni, Elisabetta, Whitener, Bradley, Giannini, Olivier, Ceschi, Alessandro, Ferrari, Paolo, Franzetti-Pellanda, Alessandra, Biggiogero, Maira, Garzoni, Christian, Zappi, Stephanie, Bernasconi, Luca, Kim, Min Jeong, Schnell, Gretja, Czudnochowski, Nadine, Franko, Nicholas, Logue, Jennifer K, Yoshiyama, Courtney, Stewart, Cameron, Chu, Helen, Schmid, Michael A, Purcell, LIsa A, Snell, Gyorgy, Lanzavecchia, Antonio, Diamond, Michael, Corti, Davide, Veesler, David
• Format: Journal Article Paper
• Language: English
• Published: United States Cold Spring Harbor Laboratory Press 27.02.2023; Cold Spring Harbor Laboratory
• Edition: 1.2
• Subjects: ACE2; Angiotensin-converting enzyme 2; Antibodies; Biotechnology; Immune imprinting; Immunological memory; Immunology; Lymphocytes B; Membrane fusion; Memory cells; Severe acute respiratory syndrome coronavirus 2; Vaccines

Currently circulating SARS-CoV-2 variants acquired convergent mutations at receptor-binding domain (RBD) hot spots. Their impact on viral infection, transmission, and efficacy of vaccines and therapeutics remains poorly understood. Here, we demonstrate that recently emerged BQ.1.1. and XBB.1 variant...